Vis enkel innførsel

dc.contributor.authorTran, Khanh Bao
dc.contributor.authorLang, Justin J.
dc.contributor.authorCompton, Kelly
dc.contributor.authorKisa, Adnan
dc.contributor.authorXu, Rixing
dc.contributor.authorAcheson, Alistair R
dc.contributor.authorHenrikson, Hannah Jacqueline
dc.contributor.authorKocarnik, Jonathan M.
dc.contributor.authorKisa, Sezer
dc.contributor.authorPenberthy, Louise
dc.contributor.authorRisk Factors Collaborators, GBD 2019 Cancer
dc.date.accessioned2022-10-06T09:12:19Z
dc.date.available2022-10-06T09:12:19Z
dc.date.created2022-08-19T17:08:07Z
dc.date.issued2022-08-18
dc.identifier.citationThe Lancet. 2022, .en_US
dc.identifier.issn0140-6736
dc.identifier.issn1474-547X
dc.identifier.urihttps://hdl.handle.net/11250/3024238
dc.description.abstractBackground: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods: The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk–outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings: Globally, in 2019, the risk factors included in this analysis accounted for 4·45 million (95% uncertainty interval 4·01–4·94) deaths and 105 million (95·0–116) DALYs for both sexes combined, representing 44·4% (41·3–48·4) of all cancer deaths and 42·0% (39·1–45·6) of all DALYs. There were 2·88 million (2·60–3·18) risk-attributable cancer deaths in males (50·6% [47·8–54·1] of all male cancer deaths) and 1·58 million (1·36–1·84) risk-attributable cancer deaths in females (36·3% [32·5–41·3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20·4% (12·6–28·4) and DALYs by 16·8% (8·8–25·0), with the greatest percentage increase in metabolic risks (34·7% [27·9–42·8] and 33·3% [25·8–42·0]). Interpretation: The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden.en_US
dc.description.sponsorshipBill & Melinda Gates Foundationen_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.ispartofseriesThe Lancet;Volume 400, Issue 10352
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectCancer burdenen_US
dc.subjectRisk factorsen_US
dc.subjectCancer preventionen_US
dc.subjectDisability-adjusted life-yearsen_US
dc.subjectRisk assessmentsen_US
dc.subjectRisk-attributable cancer deathsen_US
dc.titleThe global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019en_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2022 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doihttps://doi.org/10.1016/S0140-6736(22)01438-6
dc.identifier.cristin2044576
dc.source.journalThe Lanceten_US
dc.source.volume400en_US
dc.source.issue10352en_US
dc.source.pagenumber563-591en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal